Clinical Trials In Virginia
Discover hundreds of clinical trials in Virginia.
Search clinical trials in Virginia by city, condition or phase.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT04873362
Conditions
Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Atezolizumab
Trastuzumab Emtansine
Placebo
Trastuzumab
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Sponsor:
Oana Danciu
Location:
Code:
NCT05467891
Conditions
Locoregional Recurrence
Hormone Receptor-positive Breast Cancer
HER2-negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Ribociclib
Fulvestrant
Anastrozole
Letrozole
Exemestane
Evaluating the Anticancer Learning Circle Lifestyle Program in Endometrial Cancer Survivors
Sponsor:
University of Virginia
Location:
Code:
NCT06550791
Conditions
Neoplasm, Uterine
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Anticancer Learning Circle
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Location:
Code:
NCT05285891
Conditions
Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Ocrelizumab
Placebo for Ocrelizumab
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
Sponsor:
Bellus Health Inc. - a GSK company
Location:
Code:
NCT05599191
Conditions
Refractory Chronic Cough
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BLU-5937
Placebo
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Sponsor:
Edgewise Therapeutics, Inc.
Location:
Code:
NCT05291091
Conditions
Becker Muscular Dystrophy
Eligibility Criteria
Sex: Male
Age: 12 - 50
Healthy Volunteers: Not accepted
Interventions
Sevasemten 10 mg
Sevasemten 5 mg
Sevasemten 12.5 mg
Placebo
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
Sponsor:
Virginia Commonwealth University
Location:
Code:
NCT06212791
Conditions
Paroxysmal Atrial Fibrillation
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Self- Report Evaluation-Duke Activity Status Index
Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire
Cardiopulmonary exercise test (CPET)
Transthoracic echocardiogram
Ambulatory cardiac rhythm assessment
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Sponsor:
Seagen Inc.
Location:
Code:
NCT05208762
Conditions
Carcinoma, Non-Small-Cell Lung
Squamous Cell Carcinoma of the Head and Neck
Esophageal Squamous Cell Carcinoma
Ovarian Neoplasms
Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
PF-08046054
pembrolizumab